LCL-161 is a second mitochondria-derived activator of caspases (SMAC) mimetic that binds to cIAP1 and cIAP2 (members of the inhibitors of apoptosis family of proteins, often upregulated in many cancers) and initiates their destruction. This compound exhibits anticancer chemotherapeutic activity by inducing apoptosis in in vitro models of lymphoid cancers. LCL-161 also activates human PXR and induces activity of CYP3A4/5.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.